• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Silva Francisco bought $10,229 worth of shares (8,308 units at $1.23), increasing direct ownership by 6% to 155,759 units (SEC Form 4)

    4/10/24 5:16:36 PM ET
    $BRTX
    Managed Health Care
    Health Care
    Get the next $BRTX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Silva Francisco

    (Last) (First) (Middle)
    C/O BIORESTORATIVE THERAPIES, INC.
    40 MARCUS DRIVE

    (Street)
    MELVILLE NY 11747

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    BioRestorative Therapies, Inc. [ BRTX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    VP of Research and Development
    3. Date of Earliest Transaction (Month/Day/Year)
    04/08/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 04/08/2024 P 476 A $1.13 147,927 D
    Common Stock 04/08/2024 P 1,232 A $1.17 149,159 D
    Common Stock 04/09/2024 P 6,600 A $1.25 155,759 D
    Common Stock 12,136 I IRA
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option $3,000 (1) 10/23/2024 Common Stock 9 9 D
    Stock Option $3,000 (1) 09/04/2025 Common Stock 6 6 D
    Stock Option $3,000 (1) 06/10/2026 Common Stock 15 15 D
    Stock Option $3,000 (1) 07/12/2027 Common Stock 20 20 D
    Stock Option $3,000 (1) 10/29/2028 Common Stock 25 25 D
    Stock Option $5.08 (1) 03/18/2031 Common Stock 293,479 293,479 D
    Stock Option $5.08 (2) 11/04/2031 Common Stock 42,059 42,059 D
    Stock Option $2.91 (3) 02/17/2033 Common Stock 106,762 106,762 D
    Stock Option $1.45 (4) 02/13/2034 Common Stock 394,737 394,737 D
    Explanation of Responses:
    1. The option is currently exercisable.
    2. The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 and 21,029 shares in eight nearly equal quarterly installments beginning November 4, 2022 and continuing every three months thereafter until fully vested.
    3. The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested.
    4. The option vests and becomes exercisable to the extent of 197,369 shares on February 13, 2024 and 197,368 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested.
    /s/ Francisco Silva 04/10/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BRTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BRTX

    DatePrice TargetRatingAnalyst
    12/1/2021$37.00Buy
    Roth Capital
    More analyst ratings

    $BRTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioRestorative Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

      MELVILLE, N.Y., May 14, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the first quarter ended March 31, 2025 and provided an update on its business. "We have continued to execute well across our business, including the achievement of key clinical program milestones, since the start of 2025," said Lance Alstodt, the Company's Chief Executive Officer. "Moving forward, we remain focused on aggressively executing our growth strategy while carefully managing our resources, and we see many potential value e

      5/14/25 4:05:00 PM ET
      $BRTX
      Managed Health Care
      Health Care
    • Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data

      MELVILLE, N.Y., May 13, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that preliminary 26-, 52- and 104-week blinded preliminary data from the first 15 patients with chronic lumbar disc disease ("cLDD") enrolled in the ongoing Phase 2 clinical trial of BRTX-100 was recently presented by Francisco Silva, Vice President of Research and Development, at the International Society for Cell & Gene Therapy ("ISCT") 2025 Annual Meeting. No serious adverse events (SAEs) were reported, and there was no dose (40

      5/13/25 9:15:00 AM ET
      $BRTX
      Managed Health Care
      Health Care
    • BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025

      MELVILLE, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its first quarter 2025 financial results after market close on Wednesday, May 14, 2025. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update. First Quarter 2025 Results Conference Call Details: Date:Wednesday, May 14, 2025Time:4:30 p.m. ETDomestic:1-888-506-0062International:1-973-528-0011Access Code:924151   The call will also

      5/8/25 4:30:00 PM ET
      $BRTX
      Managed Health Care
      Health Care

    $BRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital initiated coverage on BioRestorative Therapies with a new price target

      Roth Capital initiated coverage of BioRestorative Therapies with a rating of Buy and set a new price target of $37.00

      12/1/21 10:21:36 AM ET
      $BRTX
      Managed Health Care
      Health Care

    $BRTX
    SEC Filings

    See more

    $BRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form 10-Q filed by BioRestorative Therapies Inc.

      10-Q - BioRestorative Therapies, Inc. (0001505497) (Filer)

      5/14/25 4:30:22 PM ET
      $BRTX
      Managed Health Care
      Health Care
    • BioRestorative Therapies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)

      5/14/25 4:11:19 PM ET
      $BRTX
      Managed Health Care
      Health Care
    • BioRestorative Therapies Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)

      4/21/25 4:08:50 PM ET
      $BRTX
      Managed Health Care
      Health Care
    • SEC Form SC 13D/A filed by BioRestorative Therapies Inc. (Amendment)

      SC 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)

      3/6/24 4:34:22 PM ET
      $BRTX
      Managed Health Care
      Health Care
    • SEC Form SC 13D/A filed by BioRestorative Therapies Inc. (Amendment)

      SC 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)

      2/15/24 4:43:54 PM ET
      $BRTX
      Managed Health Care
      Health Care
    • SEC Form SC 13D/A filed by BioRestorative Therapies Inc. (Amendment)

      SC 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)

      2/15/24 4:40:53 PM ET
      $BRTX
      Managed Health Care
      Health Care

    $BRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Rosa David A

      4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)

      2/19/25 4:33:37 PM ET
      $BRTX
      Managed Health Care
      Health Care
    • SEC Form 4 filed by Director Williams Patrick F.

      4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)

      2/19/25 4:31:06 PM ET
      $BRTX
      Managed Health Care
      Health Care
    • SEC Form 4 filed by Director Kukekov Nickolay V.

      4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)

      2/19/25 4:29:24 PM ET
      $BRTX
      Managed Health Care
      Health Care

    $BRTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Silva Francisco bought $10,229 worth of shares (8,308 units at $1.23), increasing direct ownership by 6% to 155,759 units (SEC Form 4)

      4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)

      4/10/24 5:16:36 PM ET
      $BRTX
      Managed Health Care
      Health Care
    • Broadrick Dale bought $206,023 worth of shares (160,000 units at $1.29) (SEC Form 4)

      4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)

      2/12/24 9:26:34 AM ET
      $BRTX
      Managed Health Care
      Health Care
    • Broadrick Dale bought $162,255 worth of shares (120,000 units at $1.35), increasing direct ownership by 37% to 447,045 units (SEC Form 4)

      4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)

      2/9/24 8:00:31 AM ET
      $BRTX
      Managed Health Care
      Health Care

    $BRTX
    Leadership Updates

    Live Leadership Updates

    See more
    • BioRestorative Therapies Announces the Appointment of Robert Paccasassi to Vice President of Quality Assurance/Regulatory Compliance

      MELVILLE, N.Y., Jan. 11, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the "Company" or "BioRestorative") (NASDAQ:BRTX), a life sciences company focused on stem cell-based therapies, today announced that Robert Paccasassi has been appointed Vice President of Quality Assurance/Regulatory Compliance. Mr. Paccasassi will lead quality initiatives through the next phase of the Company's growth as patient enrollment is initiated for the Phase 2 clinical trial to treat chronic lumbar disc disease. Mr. Paccasassi has over 25 years of biotech operations and combined experience in Quality Assurance, Regulatory Compliance, and Manufacturing. Prior to joining BioRestorative, Mr. Paccasassi

      1/11/22 6:00:00 AM ET
      $BRTX
      Managed Health Care
      Health Care
    • BioRestorative Therapies Appoints Robert Kristal as Chief Financial Officer

      MELVILLE, N.Y., Nov. 10, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the "Company") (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced that it has appointed Robert Kristal to the position of Chief Financial Officer. Mr. Kristal brings an extensive array of strategic and financial markets experience to the Company, including a background in advising global public life sciences companies in corporate finance, operations management systems, and strategic collaborations. Mr. Kristal is an experienced and versatile Wall Street and Bay St. professional who has built teams in both institutional sales and equity research at firms which

      11/10/21 6:00:00 AM ET
      $BRTX
      Managed Health Care
      Health Care

    $BRTX
    Financials

    Live finance-specific insights

    See more
    • BioRestorative Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

      MELVILLE, N.Y., May 14, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the first quarter ended March 31, 2025 and provided an update on its business. "We have continued to execute well across our business, including the achievement of key clinical program milestones, since the start of 2025," said Lance Alstodt, the Company's Chief Executive Officer. "Moving forward, we remain focused on aggressively executing our growth strategy while carefully managing our resources, and we see many potential value e

      5/14/25 4:05:00 PM ET
      $BRTX
      Managed Health Care
      Health Care
    • BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025

      MELVILLE, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its first quarter 2025 financial results after market close on Wednesday, May 14, 2025. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update. First Quarter 2025 Results Conference Call Details: Date:Wednesday, May 14, 2025Time:4:30 p.m. ETDomestic:1-888-506-0062International:1-973-528-0011Access Code:924151   The call will also

      5/8/25 4:30:00 PM ET
      $BRTX
      Managed Health Care
      Health Care
    • BioRestorative Therapies Reports 2024 Financial Results and Provides Business Update

      MELVILLE, N.Y., March 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the year ended December 31, 2024 and provided an update on its business. "2024 was a transformative year for BioRestorative, highlighted by significantly improved financial performance and meaningful clinical program advancement," said Lance Alstodt, BioRestorative's Chief Executive Officer. "Looking ahead, we remain focused on aggressively executing our growth strategy, and very much look forward to updating investors as we progr

      3/27/25 4:05:00 PM ET
      $BRTX
      Managed Health Care
      Health Care